Sells enzyme-replacement therapies for Gaucher and Fabry diseases to pharmaceutical partners, and develops drug candidates for rare diseases.
10-K for FY2025, filed Mar 18, 2026To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elelyso®…View ↗
Elelyso, our first commercial product, is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human…View ↗
Elfabrio, our second commercial product, for the treatment of adult patients with Fabry disease, is our proprietary, chemically modified…View ↗
We have partnered with Chiesi for the development and commercialization of Elfabrio for the treatment of Fabry disease through two…View ↗
Product sales are the main source: customers pay for finished drug products on delivery, with payment terms generally 45 days or less. License and R&D arrangements also bring upfront payments, development-cost reimbursements and milestones.
10-K for FY2025, filed Mar 18, 2026The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon…View ↗
The consideration promised in a contract with a Company’s customer is based on either fixed amounts or variable amounts. Variable amounts…View ↗
Under each of the Chiesi Agreements, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of…View ↗
We have partnered with Chiesi for the development and commercialization of Elfabrio for the treatment of Fabry disease through two…View ↗
10-K for FY2025, filed Mar 18, 2026
FY2025 revenue by product or service ↗$52.7M
10-K for FY2025, filed Mar 18, 2026
$52.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
GOODS
Sold outright
10-K for FY2025, filed Mar 18, 2026 |
98%
FY2022: 53%
|
GOODS, FY2025
$51.8M Sources
|
Sold outright |
|
LICENSE AND R&D SERVICES
|
1.8%
FY2022: 47%
|
LICENSE AND R&D SERVICES, FY2025
$942K Sources
|
Pfizer and Fiocruz buy Elelyso directly, while Chiesi buys Elfabrio and handles its global commercialization and distribution; Protalix retains Elelyso distribution rights in Brazil.
10-K for FY2025, filed Mar 18, 2026Our sales of Elelyso to Pfizer and Fiocruz are made at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and…View ↗
We have partnered with Chiesi for the development and commercialization of Elfabrio for the treatment of Fabry disease through two…View ↗
Under the terms of the Chiesi Agreements, Chiesi is solely responsible for the global commercialization and medical programs of Elfabrio…View ↗
No. It lost $6.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
Total revenues of approximately $78.0 million to $83.0 million, including the $25.0 million milestone payment received from Chiesi in Q1…View ↗
Growing. Revenue grew 38% in 4 years, from $38.4M in FY2021 to $52.7M in FY2025, about 8% a year.
Fabry product enters commercialization
The older report described the Fabry treatment as a late-stage candidate awaiting regulatory decisions. The latest report describes it as an approved commercial product.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 18, 2026Our proprietary ProCellEx platform is being used to manufacture our approved and marketed product, Elelyso®, for the treatment of Gaucher…View ↗
Broader development approaches
The older report emphasized genetically engineering or chemically modifying recombinant proteins, primarily through ProCellEx. The latest report also describes small molecules, antibodies and exploration of other platform technologies.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 18, 2026Our strategic focus is to develop tailored complex recombinant therapeutic proteins primarily produced through ProCellEx while genetically…View ↗
Competes with Sanofi Genzyme, Takeda, Actelion, Amicus, Sangamo Therapeutics, Amgen, Swedish Orphan Biovitrum, Crucell, Dyadic International, Pfenex, iBio, Medicago, and Eleva Biologics
10-K for FY2025, filed Mar 18, 2026With respect to Gaucher disease, we face competition primarily from two ERTs, Sanofi Genzyme’s Cerezyme and Takeda’s (Shire) Vpriv. In…View ↗
Loading...